- Home
- EZGO vs TVRD Comparison
EZGO vs TVRD Comparison
Compare EZGO & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EZGO | TVRD |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Motor Vehicles | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.9M | 36.8M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | EZGO | TVRD |
|---|---|---|
| Price | $1.24 | $3.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | 8.1K | ★ 38.4K |
| Earning Date | 07-01-2025 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.06 | $3.38 |
| 52 Week High | $2.40 | $43.65 |
Technical Indicators
Market Signals| Indicator | EZGO | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 24.75 | 42.07 |
| Support Level | $0.12 | N/A |
| Resistance Level | $2.11 | $4.13 |
| Average True Range (ATR) | 0.08 | 0.25 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 15.09 | 25.00 |
Price Performance
Historical ComparisonAbout EZGO EZGO Technologies Ltd.
EZGO Technologies Ltd is engaged in the sale of e-bicycles and battery and e-bicycle rentals, complemented by the sale of battery packs, battery cell trading and charging pile business. Its product categories include e-bicycle, Intelligent unmanned patrol car, e-motorcycle and e-moped and urban style e-tricycle. Its segments include the Battery cells and packs, electronic control system and intelligent robot segment. and the E-bicycle sales segment. The company generates maximum revenue from the Battery cells and packs segment.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.